Demagrozumab, another monoclonal anti-myostatin antibody, was developed and tested in phase 2 clinical trial in boys with Duchenne muscular dystrophy, but as it only resulted in non-significantly increased muscle volume and no improvement in muscle function, the trial was terminated early [269]. This evidence concerns the gene MSTN and Duchenne muscular dystrophy.